Share Name Share Symbol Market Type Share ISIN Share Description
Eco Animal Health Group Plc LSE:EAH London Ordinary Share GB0032036807 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 385.00p 370.00p 400.00p - - - 0 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 74.6 15.2 17.6 21.9 260

Eco Animal Health Share Discussion Threads

Showing 201 to 224 of 1050 messages
Chat Pages: Latest  18  17  16  15  14  13  12  11  10  9  8  7  Older
DateSubjectAuthorDiscuss
11/5/2011
08:27
All quiet on the EAH front. I thought this FT article was intesting in that there are two companies actively seeking acquisitions on the animal health front: Sanofi to expand animal health business //10 May 2011 Sanofi-Aventis plans to cut costs and expand its animal health business through acquisitions as it fully integrates Merial after the collapse of its longstanding joint venture with Merck of the US, The Financial Times writes As of Friday May 6, Sanofi-Aventis shareholders approved a name change. From now on the company is known as Sanofi. Chris Viehbacher, chief executive of the French pharmaceutical group, told the Financial Times there was scope for "synergy" in back office operations, manufacturing, marketing, and research and development. He said the failure of the partnership meant Sanofi-Aventis would seek new takeover targets in animal health and plan to grow, notably in emerging markets where animal health sales contributed a smaller proportion than other divisions in the group. Failure reasons In the first detailed comments by either company on the reasons for the failure, Viehbacher said that the failure to recombine the two companies' animal health divisions was caused by difficulties in clearly defining market share and concentration in a way that permitted international regulatory approvals. The process led to repeated delays and Viehbacher said that one cannot put a business on hold, stressing that both companies would have preferred to maintain the joint venture. The current structure allows Sanofi-Aventis to fully consolidate its animal health operations. Seeking acquisitions He said Merial was likely to seek acquisitions "probably not of significant size" as it expanded, stressing that it generated only a fifth of its sales in emerging markets compared with a third for the group overall. It would also seek closer links to joint development of human and animal treatments.
audigger
06/4/2011
17:46
I have more experience with EPA aprpovals than FDA. EPA now operate a fee-paying system which places an obligation on them to evaluate new applications within a defined timeframe. That said if the agency rules the database incomplete the onus is back on the registrant to address the data gaps and timelines change. I'm not sure if FDA had open questions on Eco's data that needed to be addressed by the company or if the delay was purely down to FDA struggling to meet its work load. If its the latter, you would hope that ECO aren't punished in terms of time to off-patent. I'm working on the premise that approval will be granted this year, but have no insight as to when
audigger
06/4/2011
15:51
Tightly held stock, mm's short and news around the corner.I have no doubt that Aivlosin will receive FDA approval but when I can't be sure, although I suspect sooner rather than later.The fact that the company haven't put a news release out recently indicates to me that they must be very close to achieving approval.
ltinvestor
06/4/2011
15:36
Au. I thought we would have FDA news by now??
joeblogg2
06/4/2011
15:34
Nice to see this gaining some upward momentum again after the drift down. Will be interesting to see if it can get to 280 again even without FDA news. With FDA news it could go 300+ very quickly
audigger
14/3/2011
14:47
Its good to see this kind of proactive update. I was wondering if the big fall this am was due to concerns over the Japanese side of the business. This update is reassuring. However, it doesn't feel appropriate to be too focused on the impact on personal investments given awful events in Japan.
audigger
11/2/2011
15:49
Agreed. Patience required!
topvest
11/2/2011
15:30
Very illiquid stock so when they finally receive FDA approval it will,imho, go up many times todays fall.
ltinvestor
11/2/2011
13:44
News leaking ? However minimal volume. BBB.
pugugly
11/2/2011
09:30
Ouch, that's a bit more than a drift!
audigger
08/2/2011
19:00
I guess its not surprising that this will drift back down after the recent surge whilst awaiting US approval. Sounds like they are on-track for another good set of results. Trying to decide when is a good time to add. Thinking I will wait a few weeks with an expectation it will drift lower. I think the market is also over-due a downward correction so, if that happens, they may become even cheaper. Time will tell!
audigger
04/2/2011
10:20
Thursday, February 03, 2011 ECO Animal Health: growing fast while awaiting US launch The livestock therapeutic specialist is continuing organic growth in China, Latin America and India. In the shorter term, investors will want to look out for news of US regulatory approval for its flagship product Aivlosin this year as well as full-year results that are expected to show a substantial increase in both turnover and profits. Longer term, a trade sale may be on the cards, chairman Peter Lawrence tells Proactive Investors. http://www.proactiveinvestors.co.uk/companies/news/25217/eco-animal-health-growing-fast-while-awaiting-us-launch-25217.html
aim_trader
12/1/2011
22:55
Positively flying!
audigger
12/1/2011
20:26
Absolutely, going vertical!
topvest
11/1/2011
12:39
we are off again
shroder
05/1/2011
15:23
joeblogg2 - The results in August mentioned FDA approval in the "current financial year" . This was a month or so before the "heavy workload " statement regarding the FDA . I suppose this could in theory mean approval not until after March ....
roverite12
05/1/2011
13:16
Research is ongoing and results will be published in due course according to the last report on 8/12/10.
ltinvestor
05/1/2011
12:44
Someone has taken to these in the new year. Moves quickly when it gets going this one!
topvest
05/1/2011
11:41
I thought the US approval was expected before 2010, any ideas as to delay? thks!!
joeblogg2
05/1/2011
11:36
Vulgaris, given the cost of clinical trials, what evidence do you think would be needed from the raft of ongoing screens to justify initiating a trial? Is it a given that clinical trials would be required? I guess they would if their are no existing human data for Aivlosin although not sure if the primary focus would be safety or efficacy? Either way, it seems the share price is heading north in big leaps!
audigger
05/1/2011
11:25
Itinvestor. There are assertions that macrolide antibiotcs have some immun-modulatory /anti-inflammatory effect that may be relevant for influenza -- see e.g. http://www.ncbi.nlm.nih.gov/pubmed/16835706, along with the more specific assertions re. activity in cellular compartments made in the the patent and e.g. in for clarithromycin in http://www.ncbi.nlm.nih.gov/pubmed/20040578 However: 1) Macrolides have long beeen used in human respiratory infections. Most of these infection are viral not bacterial and the accepted view is that antibiotics are being mis-prescribed in these viral cases. If macrolides had a dramatic effect irrespective of whether the infection was viral or bacterial, this would have come to light in 50 years of use. Most obviously respiratory infection trials, (mis)including many patients with viral infections would have tended to favour macrolides over penicillin, where there is no assertion of anti-viral activity----- And they don't. Morevoer, were there serious antiival activity, companies like Pfizer (which had the patent on azithromycin) would have exploited it to the hilt esp when public health agencies began saying 'Don't prescribe for coughts & colds; they're viral'). 2) A patent, put together on some prima facie evidence, is not the same thing as a controlled trial and I can find now published controlled trial of Aivlosin in this context. I hold the stock long term, as part of an IHT mitigation strategy. I would be delighted if they got a boost from antiviral activity. But, I've also got 30+ years of expereince working on antibiotics and wouldn't bet the bank this flu assertion, interesting as it is!
vulgaris
04/1/2011
20:14
The patent makes intersting reading. Its not my field of expertise but the patent does suggest a mode of action for antiviral activity based on disruption of intralysosomal pH and prevention of replication rather than any enhancement of the immune system. What I find interesting is that it was the observation of antiviral efficacy in pigs being treated for bacterial infection that triggered this additional research. I've no idea how unique such an observation may be, but it suggests that tylvalosin may be more efficacious than some of its counterparts which may be more about bioavailability than intrinsic potency against the target. If this did prove a commercially viable option, then the upside would be huge. I'm invested soleley on the basis of the antibacterial application and the growth/profit that will come from US approval. Anything in addition to this would be a bonus!
audigger
04/1/2011
17:35
Vulgaris.Just following on from my previous post there is evidence that macrolide anti biotics have shown antiviral activity eg tilmocosin which was found to be too toxic.A US patent application was applied for in January 2010 regarding the antiviral properties of Aivlosin and is worth reading.The application number is 2010/0010080.
ltinvestor
04/1/2011
17:17
The Virology dept at Cambridge have been working on the antiviral properties of Aivlosin having received a £500k grant from the Medical Research Council.In its latest release Eco are continuing this research,I presume, as a result of findings.It appears to be active against the influenza virus and several other viruses and so is more specific than a general immune system stimulant.
ltinvestor
Chat Pages: Latest  18  17  16  15  14  13  12  11  10  9  8  7  Older
Your Recent History
LSE
EAH
Eco Animal..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190820 06:17:16